Hillstream BioPharma announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the company. The company intends to use the net proceeds from the offering for the advancement of HSB-1216, the development of other product candidates in the company’s pipeline (HSB-3215 and HSB-1940), for general corporate purposes, and for working capital. ThinkEquity is acting as sole book-running manager for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HILS:
- Hillstream BioPharma Announces Pricing of Public Offering
- Hillstream BioPharma Announces Proposed Public Offering
- Hillstream BioPharma selects OncoBay to advance development of HSB-1216
- Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
- Hillstream BioPharma announces pharmacokinetic data of HSB-1216